Clinical trials: Severe Pneumonia
Coronavirus Disease 2019
Autoimmunity Contributes to the Severe Progression of COVID-19
Although elderliness and chronic comorbidities such as hypertension, diabetes, cardiovascular diseases and respiratory diseases, are known risk factors for severe progression of COVID-19, it still remains puzzling on why younger…
- Trial name
- NCT04967781
- Testing
- autoimmunity
- Where
- China
- Volunteers
- 162 people
- Sponsor
- Zhongnan Hospital
SARS-CoV Infection, Severe Acute Respiratory Syndrome (SARS) Pneumonia
Methylprednisolone in the Treatment of Patients With Signs of Severe Acute Respiratory Syndrome in Covid-19
This is a double-blind, randomized, placebo-controlled, phase IIb clinical trial to assess the efficacy of injectable methylprednisolone sodium succinate (MP) in patients with severe acute respiratory syndrome (SARS) in COVID-19…
- Trial name
- MetCOVID (NCT04343729)
- Testing
- Methylprednisolone Sodium Succinate
- Where
- Brazil
- Volunteers
- 416 people
- Sponsor
- Fundação de Medicina Tropical Dr. Heitor Vieira Dourado
COVID-19
Zilucoplan® in Improving Oxygenation, Short-, Longterm Outcome of COVID19 Patients With Acute Hypoxic Respiratory Failure
The study is a randomized controlled, open-label trial comparing subcutaneous Zilucoplan® with standard of care to standard of care alone.
- Trial name
- ZILU-COV (NCT04382755)
- Testing
- Zilucoplan®
- Where
- 9 sites in Belgium
- Volunteers
- 81 people
- Sponsor
- University Hospital, Ghent
SARS-CoV Infection
Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection
The purpose of this research is to identify whether or not Angiotensin Receptor Blockers (ARB) can halt the progression to respiratory failure requiring transfer into the intensive care unit (ICU), as well as halt mechanical…
- Trial name
- NCT04340557
- Testing
- Losartan
- Where
- 3 sites in United States
- Volunteers
- 31 people
- Sponsor
- Sharp HealthCare
Covid19, SARS-CoV Infection
Italian Web-based Cross-sectional Survey on COVID-19
The outbreak of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) that started in late December 2019 in the Hubei province of China caused millions of cases worldwide in just a few months, and evolved into a real…
- Conditions
- Covid19, SARS-CoV Infection, Survey, Family Life, Epidemic Disease
- Trial name
- EPICOVID19 (NCT04471701)
- Testing
- Environmental exposure and clinical features
- Where
- Italy
- Volunteers
- 200,000 people, healthy volunteers welcome
- Sponsor
- Institute of Biomedical Technologies-National Research Council, Italy
Pneumonia
Zinc as Adjunct to Treatment of Pneumonia
The propose of this study is to evaluate if zinc given as an adjunct to standard treatment of severe pneumonia in young children shortens the duration and reduces treatment failure, and if these effects are pathogen-dependant.
- Trial name
- EcuaPAZ (NCT00513929)
- Testing
- Zinc sulphate
- Where
- Ecuador
- Volunteers
- 450 people
- Sponsor
- Corporacion Ecuatoriana de Biotecnologia
Ventilator-Associated Pneumonia (VAP)
Immediate Versus Substantiated Antibiotic Therapy in Suspected Non-Severe Ventilator-Associated Pneumonia
Ventilator-associated pneumonia is the leading nosocomial infection in the intensive care units, and is associated with prolonged mechanical ventilation and overuse of antibiotics.
- Trial name
- POSTPONE (NCT06743529)
- Testing
- control group, Conservative strategy
- Where
- 42 sites in France, Guadeloupe
- Volunteers
- 686 people
- Sponsor
- Nantes University Hospital
Severe Pneumonia
Reparixin in COVID-19 Pneumonia - Efficacy and Safety
Phase 2 Study Objectives: efficacy and safety of of Reparixin treatment as compared to the control arm in adult patients with severe COVID-19 pneumonia Phase 3 Study Objectives: efficacy and safety of Reparixin treatment as…
- Trial name
- NCT04794803
- Testing
- Reparixin, Standard of care
- Where
- 4 sites in Brazil, Italy
- Volunteers
- 56 people
- Sponsor
- Dompé Farmaceutici S.p.A
Covid19
COVID-19 Soliris Expanded Access Protocol
This protocol provides participants with COVID-19 access to Soliris.
- Trial name
- NCT04802083
- Testing
- Eculizumab
- Sponsor
- Alexion Pharmaceuticals, Inc.
Chronic Obstructive Pulmonary Disease
Efficacy and Safety of Two Fixed Dose Combinations of Aclidinium Bromide With Formoterol Fumarate
The purpose of this multicenter, dose-ranging study is to compare two Fixed-Dose Combinations of aclidinium bromide and formoterol fumarate with placebo, aclidinium bromide and formoterol fumarate, all administered BID in…
- Trial name
- ALIGHT-COPD (NCT01078623)
- Testing
- Aclidinium 200 μg / formoterol 12 μg, Formoterol 12 μg, Aclidinium 200 μg
- Where
- 10 sites in Czechia, Romania
- Volunteers
- 176 people
- Sponsor
- AstraZeneca
Covid19
Selenium as a Potential Treatment for Moderately-ill, Severely-ill, and Critically-ill COVID-19 Patients.
Given its anti-viral, anti-oxidative, immune-enhancing, cytokine-modulating, and anticoagulant properties, the investigators hypothesize that Selenium infusion at supranutritional doses for moderately-ill, severely-ill, and…
- Trial name
- SeCOVID (NCT04869579)
- Testing
- Selenium (as Selenious Acid)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- CHRISTUS Health
Moderate Respiratory Distress, Severe Respiratory Distress
High Flow Nasal Oxygen Therapy an Implementation Study in Pediatric Wards
The purpose of this study is to prospectively evaluate the process of implementing HFNO in several MSF projects, varying according to geographical and programmatic contexts, population, health structures, human resources, and…
- Trial name
- HFNO (NCT06715423)
- Where
- Afghanistan
- Volunteers
- 960 people
- Sponsor
- Epicentre
Covid-19
Estrogen Therapy in Non-severe COVID-19 Patients
The primary objective of this study is to evaluate the effect of additional estradiol estrogen therapy on clinical response and mortality in non-severe COVID-19 patients
- Trial name
- NCT04539626
- Testing
- Estrogen Therapy
- Where
- Mexico
- Volunteers
- 44 people
- Sponsor
- CMN "20 de Noviembre"
Pneumonia, Viral
Study on Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients With Severe COVID-19 Pneumonia.
The study objective is to assess Efficacy and safety of Reparixin treatment as compared to placebo (both on top of standard treatment) in adult patients with severe COVID-19 pneumonia.
- Trial name
- NCT04878055
- Testing
- Reparixin
- Where
- 17 sites in United States, Italy
- Volunteers
- 287 people
- Sponsor
- Dompé Farmaceutici S.p.A
Respiratory Infection, Pneumonia
Efficacy and Safety of Trimodulin (BT588) in Subjects With CAP Including COVID-19 Pneumonia
The main objectives of the trial are to assess the efficacy and safety of trimodulin as adjunctive treatment to standard of care (SoC) compared to placebo plus SoC in adult hospitalized subjects with non-severe community-acquired…
- Conditions
- Respiratory Infection, Pneumonia, Community-acquired Pneumonia, Acute Respiratory Distress Syndrome
- Trial name
- TRICOVID (NCT05531149)
- Testing
- Trimodulin
- Where
- 64 sites in Argentina, Austria and 12 more
- Volunteers
- 107 people
- Sponsor
- Biotest
Covid19, Corona Virus Infection
Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and NA-831
The clinical study is designed to evaluate the safety, tolerability and pharmacokinetics of inhaled nanoparticle nanoparticle formulation of Remdesivir (GS-5734) alone and in combination with NA-831 in 48 healthy volunteers.
- Conditions
- Covid19, Corona Virus Infection, Severe Acute Respiratory Syndrome, Severe Acute Respiratory Infection
- Trial name
- NEUROSIVIR (NCT04480333)
- Testing
- Drug: NA-831 - 0.10 mg/kg, Drug: NA-831 - 0.20 mg/kg, Drug: GS-5734 - 1.00 mg/kg
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Biomed Industries, Inc.
Covid19
Evaluation of the Efficacy, Safety and Immunogenicity of Inactivated COVID 19 Vaccine(TURKOVAC) in Healthy Population of 18 and 64 Years of Age (Both Inclusive):a Randomized, Double-blind, Phase IIb Clinical Trial
The objective of this study is to evaluate the efficacy, immunogenicity and safety of two different strengths (3 µg/0.5 mL and 4,5 µg/0.5 mL) of inactivated COVID 19 Vaccine- TURKOVAC in healthy subjects following 3rd vaccination…
- Trial name
- NCT05035238
- Testing
- Triple dose vaccination by inactivated Covid19 vaccine
- Where
- Turkey (Türkiye)
- Volunteers
- healthy volunteers welcome
- Sponsor
- Health Institutes of Turkey
Chronic, Non Malignant Pain
Open Label, Safety Study of EN3270 in Patients With Moderate to Severe Non-malignant, Chronic Pain
Two stage study looking at different titration schedules in patients with moderate to severe non-malignant chronic pain. Up to 80 patients at approximately 15 centers in the US to be enrolled.
- Trial name
- NCT00485225
- Testing
- EN3270
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Durect
Severe Acute Respiratory Syndrome (SARS) Pneumonia
Stem Cell Educator Therapy Treat the Viral Inflammation in COVID-19
Currently, the growing epidemic of a new coronavirus infectious disease (Covid-19) is wreaking havoc worldwide, which is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
- Trial name
- NCT04299152
- Testing
- Stem Cell Educator-Treated Mononuclear Cells Apheresis
- Volunteers
- 20 people
- Sponsor
- Throne Biotechnologies Inc.
Coronavirus Infections
Investigating Effect of Convalescent Plasma on COVID-19 Patients Outcome: A Clinical Trial
Coronavirus disease 2019 (COVID-19) was recognized as a pandemic on March 11, 2020 by the World Health Organization. The virus that causes COVID-19 (SARS-CoV-2) is easily transmitted through person to person and there is still no…
- Trial name
- NCT04327349
- Testing
- Convalescent Plasma
- Where
- Iran
- Volunteers
- 30 people
- Sponsor
- Mazandaran University of Medical Sciences
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.